Capricor Therapeutics

Capricor Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class therapeutics for the treatment of diseases. Its lead programs target post myocardial infarction (heart attack), heart failure and Duchenne Muscular Dystrophy. As a developer of innovative therapies, Capricor Therapeutics is strategically positioned at the forefront of one of the largest segments of the U.S. healthcare industry − cardiovascular disease.
Company Growth (employees)
Type
Public
HQ
Beverly Hills, US
Founded
2005
Size (employees)
29 (est)
Capricor Therapeutics was founded in 2005 and is headquartered in Beverly Hills, US

Capricor Therapeutics Office Locations

Capricor Therapeutics has an office in Beverly Hills
Beverly Hills, US (HQ)
8840 Wilshire Blvd

Capricor Therapeutics Financials and Metrics

Capricor Therapeutics Financials

Capricor Therapeutics's revenue was reported to be $4 m in FY, 2016
USD

Revenue (Q3, 2017)

313.3 k

Net income (Q3, 2017)

(2.7 m)

EBIT (Q3, 2017)

(2.6 m)

Market capitalization (11-Dec-2017)

39.7 m

Cash (30-Sep-2017)

8.9 m
Capricor Therapeutics's current market capitalization is $39.7 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

503.2 k4.8 m5.5 m4 m

Revenue growth, %

851%15%(28%)

R&D expense

5.2 m

General and administrative expense

2.2 m
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Revenue

1 m1 m1.3 m1.8 m1.3 m1.3 m1.2 m1.1 m746.8 k880.8 k996.5 k313.3 k

R&D expense

1.4 m1.9 m2 m3.8 m3.4 m3.2 m4.3 m4.3 m4.7 m3.3 m3.1 m1.9 m

General and administrative expense

852.3 k665.7 k819.7 k1.4 m926.3 k972.8 k1.1 m1.4 m1.3 m1.2 m1.2 m1.1 m

Operating expense total

2.2 m2.5 m2.8 m5.2 m4.4 m4.2 m5.4 m5.7 m6 m4.4 m4.4 m3 m
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

1.7 m8 m5.6 m3.2 m

Accounts Receivable

187

Inventories

222.8 k235.5 k210.6 k342.9 k

Current Assets

3.7 m11.6 m14 m18.1 m
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Cash

13 m11.6 m9.8 m6.9 m5 m4.2 m11.8 m8.9 m18 m2.8 m8.3 m8.9 m

Accounts Receivable

757230823

Inventories

190.3 k

Current Assets

14 m16.4 m14.2 m25.4 m21.6 m17.7 m14.9 m11.8 m22.4 m13.5 m13.6 m15.2 m
    USDFY, 2013FY, 2014FY, 2015FY, 2016

    Net Income

    (8.9 m)(6.2 m)(12.9 m)(18.8 m)

    Depreciation and Amortization

    26.9 k41.9 k110.9 k125.7 k

    Accounts Receivable

    25 k

    Inventories

    (161.6 k)(12.6 k)24.9 k(132.3 k)
    USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q3, 2017

    Net Income

    (1.2 m)(1.5 m)(1.5 m)(3.5 m)(3.1 m)(2.9 m)(4.3 m)(4.7 m)(5.3 m)(3.7 m)(2.7 m)

    Depreciation and Amortization

    109.6 k

    Accounts Receivable

    230823

    Inventories

    190.3 k
      Y, 2017

      Financial Leverage

      -3.7 x
      Show all financial metrics

      Capricor Therapeutics Market Value History

      Capricor Therapeutics's Web-traffic and Trends

      Capricor Therapeutics Online and Social Media Presence

      Capricor Therapeutics Company Life and Culture

      You may also be interested in